Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 13

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 13
---
0.0001 par value; 626 shares authorized; 0 and 273 issued and outstanding at September 30, 2025 and December 31, 2024, respectively; No liquidation preference at September 30, 2025                     |     |               |           - |   |     |              |     218,051 |   |
| Class A common stock; $0.0001 par value; 1,000,000,000 shares authorized; 1,496,398 and 120,794 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively                                                         |     |               |         150 |   |     |              |          12 |   |
| Additional paid-in capital                                                                                                                                                                                                                      |     |               |  73,055,709 |   |     |              |  67,142,276 |   |
| Stock subscription receivable                                                                                                                                                                                                                   |     |               |           - |   |     |              |  (1,295,444 | ) |
| Accumulated deficit                                                                                                                                                                                                                             |     |               | (86,297,494 | ) |     |              | (70,917,853 | ) |
| Total stockholders’ deficit                                                                                                                                                                                                                     |     |               |  (4,543,162 | ) |     |              |  (1,894,563 | ) |
| Total liabilities and stockholders’ deficit                                                                                                                                                                                                     |     | $             |   3,911,394 |   |     | $            |   6,206,929 |   |

<div align='center'>See accompanying notes to the condensed consolidated
financial statements

Reflects a 1-for-100 reverse stock split effective January 8, 2025
and 1-for-20 reverse stock split effective June 13, 2025

1

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)</div>

|                                                            |     |            |       For the 
  Three Months 
         Ended 
 September 30, 
          2025 |   |     |            |       For the 
  Three Months 
         Ended 
 September 30, 
          2024 |   |     |            |       For the 
   Nine Months 
         Ended 
 September 30, 
          2025 |   |     |            |       For